Suppression by several synthetic polypeptides of experimental allergic encephalomyelitis induced in guinea pigs and rabbits with bovine and human basic encephalitogen

No abstract is available for this paper.

• Publication year

  1973

• Venue

  European Journal of Immunology

• Publication date

  1973-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/eji.1830030505PMID 4128127
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Species specificity in response to tryptophan modified encephalitogen.

  1972cited by this paper
• Essential Chemical Requirements for Induction of Allergic Encephalomyelitis

  1971cited by this paper
• A histological dose-response effect in guinea-pigs injected with graded amounts of basic protein and peptides from human brain.

  1971cited by this paper
• Experimental allergic encephalomyelitis: species variability of the encephalitogenic determinant.

  1971cited by this paper
• Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide

  1971cited by this paper
• Antibody response to polyalanyl determinants in tolerant rabbits.

  1971cited by this paper
• Detection of antibodies to the basic protein of human myelin by radioimmunoassay and immunofluorescence.

  1971cited by this paper
• Basic encephalitogenic protein: A simplified purification on sulphoethyl‐sephadex

  1970cited by this paper
• Localization of the active site through chemical modification of the encephalitogenic protein.

  1970cited by this paper
• Preparation of protein-bacteriophage conjugates and their use in detection of anti-protein antibodies.

  1970cited by this paper
• Allergic encephalomyelitis: immunologically specific inhibition of cellular passive transfer by encephalitogenic basic proteins.

  1970cited by this paper
• Transformation of rodent lymphoid cells by an encephalitogen of human origin.

  1969cited by this paper
• Allergic encephalomyelitis: isolation and characterization of encephalitogenic peptides from the basic protein of bovine spinal cord.

  1969cited by this paper
• Inhibition of in vitro cell migration in experimental allergic encephalomyelitis.

  1969cited by this paper
• Allergic encephalomyelitis: cleavage of the C-tryptophyl bond in the encephalitogenic basic protein from bovne myelin.

  1969cited by this paper
• Experimental allergic encephalomyelitis in the rhesus monkey. An electron microscopic study.

  1969cited by this paper
• Protective action of the encephalitogen and other basic proteins in experimental allergic encephalomyelitis.

  1968cited by this paper
• Experimental allergic encephalomyelitis and autoimmune disease.

  1966cited by this paper
• PATHOGENESIS OF EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS: INTRODUCTORY REMARKS.

  1965cited by this paper
• Studies on the chemical basis of the antigenicity of proteins. 5. Synthesis, characterization and immunogenicity of some multichain and linear polypeptides containing tyrosine.

  1962cited by this paper
• ANTIBODY STUDIES IN RABBIT ENCEPHALOMYELITIS INDUCED BY A WATER-SOLUBLE PROTEIN FRACTION OF RABBIT CORD

  1962cited by this paper
• Automatic recording apparatus for use in the chromatography of amino acids.

  1958cited by this paper
• Synthesis and chemical properties of poly-alpha-amino acids.

  1958cited by this paper
• [Pathohistology and pathogenesis of experimental allergic encephalomyelitis of monkeys].

  1957cited by this paper
• Cleavage of N-Carbobenzoxy Groups by dry Hydrogen Bromide and Hydrogen Chloride

  1952cited by this paper
• ENCEPHALOMYELITIS ACCOMPANIED BY MYELIN DESTRUCTION EXPERIMENTALLY PRODUCED IN MONKEYS

  1935cited by this paper

• Synthesis of Polypeptides and Poly(α-hydroxy esters) from Aldehydes Using Strecker Synthesis

  2023cites this paper
• The impact of translational research on the development of therapeutic agents for multiple sclerosis

  2021cites this paper
• Glatiramer Acetate: from Bench to Bed and Back.

  2019cites this paper
• The Evolving Mechanisms of Action of Glatiramer Acetate.

  2019cites this paper
• Process signatures in glatiramer acetate synthesis: structural and functional relationships

  2017cites this paper
• Development of Glatopa® (Glatiramer Acetate): The First FDA-Approved Generic Disease-Modifying Therapy for Relapsing Forms of Multiple Sclerosis

  2017cites this paper
• Two decades of glatiramer acetate: From initial discovery to the current development of generics.

  2017cites this paper
• Animal models of human disease: inflammation.

  2014cites this paper
• Analyzing the effects of laquinimod on innate and adaptive immunity in mice with experimental autoimmune encephalomyelitis

  2014cites this paper
• Immune regulation of multiple sclerosis by CD8+ T cells

  2014cites this paper
• Glatiramer acetate and therapeutic peptide vaccines for multiple sclerosis

  2014cites this paper
• Immune regulation of multiple sclerosis by CD8+ T cells

  2014cites this paper
• Design of Peptide Immunotherapies for MHC Class-II-Associated Autoimmune Disorders

  2013cites this paper
• Immunotherapy of Multiple Sclerosis

  2013influential citation
• Immunization with A91 peptide or copolymer‐1 reduces the production of nitric oxide and inducible nitric oxide synthase gene expression after spinal cord injury

  2012cites this paper
• Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)

  2011cites this paper
• Peptides and Polypeptides as Immunomodulators and Their Consequential Therapeutic Effect in Multiple Sclerosis and Other Autoimmune Diseases

  2011cites this paper
• Are current disease‐modifying therapeutics in multiple sclerosis justified on the basis of studies in experimental autoimmune encephalomyelitis?

  2010cites this paper
• Translational research in neurology and neuroscience 2010-2011.

  2010cites this paper
• Translational research in neurology and neuroscience 2010: multiple sclerosis.

  2010cites this paper
• Long-term treatment of multiple sclerosis with glatiramer acetate: natural history of the subtypes of anti-glatiramer acetate antibodies and their correlation with clinical efficacy.

  2010cites this paper
• Bovine myelin basic protein: immunochemical specificity examined by the macrophage migration inhibition test.

  2009cites this paper
• Glatiramer acetate: a novel therapeutic approach in Crohn's disease?

  2009cites this paper
• Combination therapies for multiple sclerosis: scientific rationale, clinical trials, and clinical practice

  2007cites this paper
• The translation of drug efficacy from in vivo models to human disease with special reference to experimental autoimmune encephalomyelitis and multiple sclerosis

  2007cites this paper
• Glatiramer acetate: mechanisms of action in multiple sclerosis.

  2007cites this paper
• Glatiramer acetate: mechanisms of action in multiple sclerosis.

  2007cites this paper
• The tortuous journey of a biochemist to immunoland and what he found there.

  2006cites this paper
• Treating autoimmune diseases through restoration of antigen-specific immune tolerance

  2006influential citation
• Glatiramer acetate (GA) therapy induces a focused, oligoclonal CD8+ T-cell repertoire in multiple sclerosis.

  2006cites this paper
• Immunomodulatory Vaccines Against Autoimmune Diseases

  2006cites this paper
• Glatiramer acetate therapy for multiple sclerosis: a review

  2006cites this paper
• How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis

  2006cites this paper
• Peptide 15-mers of defined sequence that substitute for random amino acid copolymers in amelioration of experimental autoimmune encephalomyelitis.

  2005cites this paper
• Glatiramer acetate in the treatment of multiple sclerosis.

  2005cites this paper
• Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis.

  2005cites this paper
• Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action.

  2005cites this paper
• Therapeutic vaccines in autoimmunity

  2004cites this paper
• Minors come of age: Minor histocompatibility antigens and graft-versus-host disease.

  2004cites this paper
• Amelioration of proteolipid protein 139-151-induced encephalomyelitis in SJL mice by modified amino acid copolymers and their mechanisms.

  2004cites this paper
• Induction of IL-10 in rat peritoneal macrophages and dendritic cells by glatiramer acetate.

  2004cites this paper
• My world through science

  2004cites this paper
• Neuroprotection and glatiramer acetate: the possible role in the treatment of multiple sclerosis.

  2004cites this paper
• Copolymer 1: an off-beat drug development story.

  2004cites this paper
• Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy

  2003cites this paper
• From Proteins and Protein Models to Their Use in Immunology and Immunotherapy

  2003cites this paper
• Behandlung der Multiplen Sklerose mit Glatiramer-Azetat

  2002cites this paper
• Interferon beta treatment in relapsing-remitting multiple sclerosis. A review.

  2002cites this paper
• Novel synthetic amino acid copolymers that inhibit autoantigen-specific T cell responses and suppress experimental autoimmune encephalomyelitis.

  2002cites this paper
• Immuntherapie der multiplen Sklerose mit Glatiramerazetat (Copaxone®)

  2002cites this paper
• Glatiramer Acetate

  2002cites this paper
• Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis.

  2002cites this paper
• A polymer as an active ingredient in a drug?-?the development of Copolymer 1 as a drug against multiple sclerosis

  2002cites this paper
• Interferon β treatment in relapsing–remitting multiple sclerosis. A review

  2002cites this paper
• Glatiramer acetate for multiple sclerosis: a comprehensive review of mechanisms and clinical efficacy

  2002cites this paper
• [Treatment of multiple sclerosis with glatiramer acetate. Current aspects of mechanisms of action, pharmacokinetics, adverse effect profile and clinical studies].

  2002cites this paper
• Glatiramer acetate.

  2002cites this paper
• Polyreactive antibodies to glatiramer acetate promote myelin repair in murine model of demyelinating disease

  2002cites this paper
• Mechanisms of action of glatiramer acetate in multiple sclerosis

  2001cites this paper
• Synthetic peptides that inhibit binding of the myelin basic protein 85-99 epitope to multiple sclerosis-associated HLA-DR2 molecules and MBP-specific T-cell responses.

  2001cites this paper
• Glatiramer acetate blocks interleukin-1-dependent nuclear factor-kappaB activation and RANTES expression in human U-251 MG astroglial cells.

  2001cites this paper
• Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone.

  2001cites this paper
• Risk-Benefit Assessment of Glatiramer Acetate in Multiple Sclerosis

  2001cites this paper
• Synthetic peptides that inhibit binding of the collagen type II 261-273 epitope to rheumatoid arthritis-associated HLA-DR1 and -DR4 molecules and collagen-specific T-cell responses.

  2000cites this paper
• Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells.

  2000cites this paper
• Structural components responsible for peptide antigenicity

  2000cites this paper
• Therapeutic apheresis in neurological disorders

  2000cites this paper
• Immunomodulation of experimental autoimmune encephalomyelitis by oral administration of copolymer 1.

  1999cites this paper
• Arthritis-Associated HLA-DR Molecules Sclerosis- and Rheumatoid Binding Motifs of Copolymer 1 to Multiple

  1999cites this paper
• Binding motifs of copolymer 1 to multiple sclerosis- and rheumatoid arthritis-associated HLA-DR molecules.

  1999cites this paper
• Effect of timing of intravenous administration of myelin basic protein on the induction of tolerance in experimental allergic encephalomyelitis.

  1999cites this paper
• Immunomodulating therapeutic approaches for multiple sclerosis.

  1998cites this paper
• Synthetic amino acid copolymers that bind to HLA-DR proteins and inhibit type II collagen-reactive T cell clones.

  1998cites this paper
• Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1.

  1998cites this paper
• Promiscuous binding of synthetic copolymer 1 to purified HLA-DR molecules

  1997cites this paper
• Binding of copolymer 1 and myelin basic protein leads to clustering of class II MHC molecules on antigen-presenting cells.

  1997cites this paper
• Copolymer 1

  1997cites this paper
• Cop 1 as a candidate drug for multiple sclerosis.

  1997cites this paper
• Copolymer-1

  1996cites this paper
• Clinical Trials Report: Central & Peripheral Nervous Systems: Drugs in development for the treatment of multiple sclerosis: antigen-specific therapies

  1996cites this paper
• The development of Cop 1 (Copaxone), an innovative drug for the treatment of multiple sclerosis: personal reflections.

  1996cites this paper
• New insights into the mechanism of action of copolymer 1 of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis

  1996cites this paper
• A synthetic random basic copolymer with promiscuous binding to class II major histocompatibility complex molecules inhibits T-cell proliferative responses to major and minor histocompatibility antigens in vitro and confers the capacity to prevent murine graft-versus-host disease in vivo.

  1996cites this paper
• New insights into the mechanism of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis.

  1996cites this paper
• Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses.

  1996cites this paper
• Copolymer-l Review of its Pharmacological Properties and Therapeutic Potential in Multiple Sclerosis

  1996cites this paper
• Synthetic copolymer 1 and myelin basic protein do not require processing prior to binding to class II major histocompatibility complex molecules on living antigen-presenting cells.

  1995cites this paper
• Therapy for multiple sclerosis.

  1995cites this paper
• Specific treatment of multiple sclerosis.

  1994cites this paper
• Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells--specificity and promiscuity.

  1994cites this paper
• Polymeric drugs as immunomodulatory vaccines against multiple sclerosis

  1993cites this paper
• T suppressor hybridomas and interleukin‐2‐dependent lines induced by copolymer 1 or by spinal cord homogenate down‐regulate experimental allergic encephalomyelitis

  1993cites this paper
• Treatment of Multiple Sclerosis with Copolymer I

  1992cites this paper
• Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein.

  1992cites this paper
• Copolymer-1-induced inhibition of antigen-specific T cell activation: interference with antigen presentation

  1992cites this paper
• Synthetic approaches to vaccines for infectious and autoimmune diseases.

  1992cites this paper
• Cross-reactions and specificities of monoclonal antibodies against myelin basic protein and against the synthetic copolymer 1.

  1991cites this paper
• A placebo‐controlled, double‐blind, randomized, two‐center, pilot trial of Cop 1 in chronic progressive multiple sclerosis

  1991cites this paper
• Cell-mediated immune response to copolymer I in multiple sclerosis measured by the macrophage procoagulant activity assay.

  1990cites this paper
• Procédé de préparation de gènes codant des polymères statistiques d'aminoacides

  1990cites this paper